secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001193125-26-126216
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna reports Q4/FY2025 results; cash $279M, SPS BLA on track for 1H 2026
---------------------------------------------------------------------------

- Net loss $37.8M Q4, $161.3M FY2025; R&D $30.0M Q4, G&A $9.3M Q4.
- Cash and equivalents $279.3M; raised $147.5M in equity and $25M from loan facility.
- SPS registrational trial met primary endpoints; BLA submission expected 1H 2026; launch-ready by YE 2026.
- Phase 3 gMG trial enrolling; first patient Dec 2025; 14 sites active across three geographies.
- Positive PMS Phase 1 data: 83% (5/6) patients achieved EDSS improvement; no high-grade CRS/ICANS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526126216/0001193125-26-126216-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526126216/kytx-20260326.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-126216

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer